2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Roswell Park Comprehensive Cancer Center endorsed a statement urging health care systems and professionals to choose HPV vaccination for cancer prevention.
This week, Roswell Park Comprehensive Cancer Center, along with 61 other National Cancer Institute (NCI)-Designated Cancer Centers, leading national organizations and the University of Puerto Rico Comprehensive Cancer Center, have endorsed a joint statement urging the nation’s health care systems, physicians, health care professionals, parents, caregivers and the public to promote and choose human papillomavirus (HPV) vaccination for cancer prevention.
“We urge physicians and families to be advocates for HPV vaccination — to get informed and get children vaccinated so we can prevent thousands of cancer cases each year,” says Roswell Park President, CEO and M&T Bank Presidential Chair in Leadership Candace S. Johnson, PhD.
“The HPV vaccine is the only vaccine we have that prevents six types of cancer, and we know it’s safe,” says cancer prevention and public health expert Elisa Rodriguez, PhD, MS, Vice President and Associate Director for Institutional Leadership at Roswell Park, who is leading a study assessing a program for HPV vaccination adoption across 20 New York State counties. “Parents and pediatricians are looking for ways to keep children healthy, and this is an important one.”
HPV vaccination is safe and works to prevent six types of cancer: oropharyngeal, cervical, anal, vaginal, vulvar and penile. Recently released National Immunization Survey (NIS)-Teen data show no gains in HPV vaccination over the last few years indicating urgent action to ensure children today are protected against HPV-related cancers they may develop in adulthood.
HPV vaccination is cancer prevention, with 90% of HPV-related cancers preventable through on-time HPV vaccination by the 13th birthday. In the United States, the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices has recommended routine HPV vaccination for females since 2006 and for males since 2011. Current HPV vaccination guidelines are for routine vaccination at ages 9 to 12. Catch-up HPV vaccination is recommended through age 26. Adults aged 27 through 45 should talk with their health care providers about HPV vaccination because some people who have not been vaccinated might benefit. The HPV vaccine series consists of two doses for children who get the first dose at ages 9–14, three doses for immunocompromised people, and three doses for those who start the series at age 15 or older. Gardasil-9 (9vHPV) the vaccine distributed in the United States.
“The HPV vaccine was and still is a huge game changer for the prevention of cervical cancer, the third most common gynecological cancer in this country,” says Roswell Park Gynecologic Oncologist Nicole Gaulin, MD. “Most people will be exposed to HPV at some point in their life. We don’t treat HPV directly because in many cases, a healthy immune system will clear the virus without lasting effects. But women with weakened immune systems, those who smoke, or older individuals may have more difficulty fighting the virus, increasing their risk for cervical, vaginal, and vulvar cancers, among others, and having the HPV vaccine is their first line of defense.” (Read more from Dr. Gaulin here.)
According to the most recent NIS-Teen data, only 63% of boys and girls ages 13-17 and only 59% of boys and girls ages 13-15 completed the HPV vaccination series in 2024, with great variability by geographic region and locale with lower coverage among children in rural areas. Nationally, HPV vaccination coverage has stagnated for the last three years and falls short of the national Healthy People 2030 goal of 80% of children aged 13-15-years-old who are vaccinated.
HPV is common. Nearly 80 million Americans — 1 out of every 4 people — are infected with HPV, a virus that causes six types of cancers. Of those millions, more than 40,000 will be diagnosed with HPV-related cancers this year and hundreds of thousands more with pre-cancers caused by HPV. Despite those staggering figures and the availability of a vaccine to prevent HPV infections, HPV vaccination coverage remains significantly lower than other recommended vaccines for this same age group in the U.S. It is not yet known in whom HPV infection will lead to cancer, but HPV vaccination is known to protect those who are vaccinated.
HPV vaccine is safe. Vaccines, like any medicine, can have side effects. Many people who get the HPV vaccine have no side effects at all. The most common side effects are usually mild, like a sore arm from the shot. Findings from many vaccine safety monitoring systems and more than 160 studies show HPV vaccines have a favorable safety profile. Currently available scientific evidence overwhelmingly supports the safety of the HPV vaccine.
HPV vaccination is effective at preventing HPV-related infections and cancers. In the U.S., where HPV vaccination coverage remains suboptimal, gains have been observed but full population benefit not yet realized. From 2008-2022, cervical pre-cancer incidence decreased 79% and higher-grade pre-cancer incidence decreased 80% among women aged 20–24 years screened for cervical cancer, the age group most likely to have been vaccinated, according to a recent article in Morbidity and Mortality Weekly Report.
To ensure protection against HPV-related cancers and move closer to elimination of HPV cancers starting with cervical cancer as a public health concern in the U.S., urgent action is needed to prevent HPV-related cancers. HPV vaccination is the best tool in the toolbox to prevent HPV-related cancers.
The call to action comes during the back-to-school period, a time during which most children aged 9-12-years-old are vaccinated against HPV and also during Gynecologic Cancer Awareness Month, which is a time to raise awareness about gynecologic cancers such as cervical, vaginal, and vulvar caused by HPV. The organizations collectively urge the following actions:
Sixty-two NCI-Designated Cancer Centers plus leading national organizations and the University of Puerto Rico Comprehensive Cancer Center endorse the joint statement and share the goal of sending a powerful message about the importance of HPV vaccination for the prevention of HPV-related cancers. HPV vaccination is safe, effective, and provides long-lasting protection against HPV-related cancers and other conditions associated with HPV.
In addition, the University of Puerto Rico Comprehensive Cancer Center has endorsed this statement.
Related Content: